Xenon: no stranger to anaesthesia

R. D. Sanders¹ ³, N. P. Franks¹ ² and M. Maze¹ ² ³*²

¹Department of Anaesthetics and Intensive Care, Faculty of Medicine, and ²Biophysics Section, Department of Biological Sciences, Imperial College London, UK. ³Magill Department of Anaesthesia, Intensive Care and Pain Management, Chelsea and Westminster Hospital, Chelsea and Westminster Healthcare NHS Trust, London, UK

*Corresponding author. E-mail: m.maze@ic.ac.uk

Br J Anaesth 2003; 91: 709–17

Keyword: anaesthesia, neuroprotection; anaesthetics gases, xenon; heart, cardiovascular stability; receptors, V-methyl-D-aspartate

Xenon derives its name from the Greek for ‘stranger’ because of its rarity, representing no more than 8.75 x 10⁻⁶% of the atmosphere or 0.0875 ppm. Discovered in 1898, it is manufactured by fractional distillation of air and is used commercially for lasers, high intensity lamps, flash bulbs, jet propellant in the aerospace industry, X-ray tubes, and in medicine. The total amount of xenon in the atmosphere would occupy around 10¹⁴ litres at atmospheric pressure, which is more than 10 million times the amount currently produced each year. Xenon has been used experimentally in clinical anaesthetic practice for more than 50 yrs.¹ Over this period of time, reports of clinical studies reveal that several hundred surgical patients have successfully received this noble gas as part of their anaesthetic regimen. Xenon’s safety and efficacy profile in this setting appears to be unequalled and only its relatively high cost has precluded its more widespread clinical use. Concerns over cost are now being mitigated by technological developments in the delivery and recycling of xenon that will permit much less total gas to be expended for each anaesthetic administration.

Over the last decade there has been renewed interest in the use of xenon as an anaesthetic, as investigators have sought to find a safe and effective substitute for nitrous oxide, which has caused environmental concerns because of its ozone-depleting properties.³³ Since then, studies have demonstrated several advantages of using xenon when compared with not only nitrous oxide, but most other potent inhalation agents. These include:

1. A pharmacokinetic benefit as a result of its extremely low blood/gas partition coefficient,²⁴ which results in a rapid onset and offset of its action.²³ ⁴⁶
2. Less cardiovascular depression.⁴ ¹⁰ ³³ ³⁵
3. Neuroprotection.⁵⁷ ⁶⁴
4. Profound analgesia.³³ ⁴⁸

This review will deal with some of the benefits of xenon anaesthesia, with a view to identifying those areas where it may be used to clinical advantage.

Mechanisms of action

Xenon potently inhibits N-methyl-D-aspartate (NMDA) receptors non-competitively, with little effect on GABA_A receptors or non-NMDA glutamatergic receptors.⁹ ¹² Franks and colleagues⁹ ¹² (Fig. 1), demonstrated that 80% xenon reduced NMDA-activated currents by approximately 60%. These results further showed that the pre-synaptic effects of xenon must be minimal, consistent with the observation that several voltage-gated ion channels in cardiac tissue are unaffected by clinically relevant concentrations of xenon.⁵⁸ Nitrous oxide has also been shown to be effective at inhibiting the NMDA receptor.³⁰

Yamakura and Harris,⁶⁷ subsequently found that both xenon and nitrous oxide can also inhibit nicotinic acetylcholine receptors (nAChR) comprising the α,β₂ subunits. It is unlikely that the analgesic action of these gases is a result of

¹Declaration of interest. Professor Maze and Professor Franks are Board members of an Imperial College spin-out company (Protexeon Ltd) that is interested in developing clinical applications for medical gases, including xenon. Both Professor Franks and Professor Maze are paid consultants in this activity. In addition, Air Products have funded, and continue to fund, work in the authors’ laboratories that bears on the actions of xenon as an anaesthetic and neuroprotectant, and Air Products has a financial stake in Protexeon Ltd.
of inhibition of nAChR because activation of these receptors elicits antinociception. Xenon (and nitrous oxide) has been reported to competitively inhibit 5HT₃A receptors expressed in *Xenopus* oocytes, but this has yet to be confirmed in mammalian cells. It is notable that these receptors have been implicated in postoperative nausea and vomiting, and in peripheral and central nociception.

It is not possible to state categorically which of these effects on ligand-gated and receptor-gated ion channels are causally linked to the anaesthetic action of xenon. As with nitrous oxide and cyclopropane, xenon distinguishes itself from all other volatile and gaseous anaesthetic agents by exerting no action at the GABAA receptor. On balance, it is likely that antagonism of the NMDA receptor is responsible, at least in part, for its anaesthetic action.

### Measuring the xenon anaesthetic state

Several surrogate measures have been advocated as indicating the depth of the anaesthetic state and the effect of xenon on these is now considered. EEG changes are similar during anaesthesia with either xenon or nitrous oxide, exhibiting attenuation of θ waves at lower concentrations, with the appearance of θ and δ wave activity at higher concentrations. The bispectral index (BIS), an electroencephalographic-derived univariate scale, is thought to reflect the level of hypnosis in anaesthetized patients. As the BIS algorithm was empirically developed from EEG recordings from ‘GABAergic anaesthetics’ (e.g. propofol), it has not fared as well in relation to general anaesthetics with NMDA antagonistic properties such as ketamine. Goto and colleagues investigated the suitability of BIS to monitor the emergence from xenon anaesthesia compared with isoflurane anaesthesia. A BIS value lower than 50 (a value normally associated with deep hypnosis) did not guarantee adequate hypnosis during xenon anaesthesia, a property shared by other ‘non-GABAergic’ anaesthetics (e.g. ketamine, nitrous oxide, and α₂ adrenergic agonists). Mid-latency auditory evoked potentials (MLAEPS) may predict wakefulness during anaesthesia, defined as the presence of a response to verbal command. Goto and colleagues randomly assigned 60 patients to receive xenon, isoflurane, sevofoflurane, or nitrous oxide supplemented with epidural anaesthesia. They found that the MLAEP is closely associated with responsiveness to verbal command during emergence from anaesthesia with xenon, isoflurane, and sevofoflurane but not with nitrous oxide. The close correlation of MLAEPs to the hypnotic state during xenon anaesthesia, suggests that this may be a more appropriate form of monitoring than BIS monitoring and highlights a further difference between xenon and nitrous oxide (for which neither system appears effective).

### Minimum alveolar concentration

In the first assessment of the MAC for xenon, Cullen and colleagues estimated a value of 71% of an atmosphere; subsequently it has been estimated to be somewhat lower at...
It is important to note that both these MAC values were determined in studies in which another inhalation anaesthetic (halothane or sevoflurane) was co-administered and thus the MAC value for xenon was extrapolated by the lowering of the MAC of the inhalation agent in the presence of xenon. While it is preferable that MAC studies be done in the absence of other anaesthetic compounds, the risk of hypoxia in a closed-circuit system with xenon at concentrations greater than 70% makes such a study unfeasible.

The MAC-awake value for xenon was determined in 90 female patients to be 33% or 0.46 times its MAC. In terms of the MAC-fraction, this is smaller than that for nitrous oxide (0.61 MAC), but greater than those for isoflurane and sevoflurane (both 0.35 MAC). The same study found that unlike nitrous oxide, xenon interacts additively with isoflurane and sevoflurane on MAC-awake. Animal studies have established MAC values for dogs (1.19 atm), rats (1.61 atm), rabbits (0.85 atm), and rhesus monkeys (0.98 atm).

**Clinical features**

**Induction and emergence**

Xenon has a blood:gas partition coefficient of only 0.115, which is significantly lower than those for other inhalation anaesthetics (nitrous oxide 0.47, sevoflurane 0.65, and desflurane 0.42). Consequently, several studies have revealed extremely short induction and emergence times for xenon anaesthesia. Induction of anaesthesia with xenon is faster than with sevoflurane (71 vs 147 s). Emergence from xenon anaesthesia is two or three times faster than that from equi-MAC concentrations of nitrous oxide/isoﬂurane or nitrous oxide/sevoflurane anaesthesia. Furthermore, prolonged xenon anaesthesia does not lengthen the emergence time. Dingley and colleagues reported a significantly quicker recovery time when compared with an equivalent depth of propofol anaesthesia (3 min 11 s compared with 25 min 23 s). The extremely rapid emergence times after xenon anaesthesia may be used to advantage not only in outpatient settings but also in cardiac surgery, where both ‘fast tracking’ and cardiovascular stability are desirable features (see below).

**Cardiovascular system**

Xenon anaesthesia is associated with remarkable cardiovascular stability, with only a clinically insignificant decrease in heart rate being reported. Lachmann suggested that the haemodynamic stability was a result of less stress-induced sympathetic stimulation, a theory supported by the observation of stable epinephrine levels during xenon anaesthesia. Compared with nitrous oxide anaesthesia, much less fentanyl was required to maintain cardiovascular stability during xenon anaesthesia. Perioperatively, plasma cortisol and epinephrine increased in the nitrous oxide group but did not change in the xenon group, despite the fact that more fentanyl was used during nitrous oxide anaesthesia. When Dingley and colleagues directly compared the cardiovascular effects of post-cardiac surgical patients sedated with either propofol or xenon, they noted that xenon caused no change in heart rate or MAP, and higher filling pressures and systemic vascular resistance were seen than were evident in propofol-sedated patients. Xenon anaesthesia compared favourably with total i.v. anaesthesia (pentobarbital and buprenorphine), with respect to haemodynamic variables in the pig.

The autonomic nervous system effects of xenon anaesthesia were compared with those caused by either isoflurane or nitrous oxide/isoﬂurane in 39 patients (ASA I–II); xenon was found to depress both sympathetic and parasympathetic transmission more than isoﬂurane at 0.8 MAC. The mechanism behind the autonomic actions of xenon has yet to be elaborated.

Ventricular function, as assessed by transoesophageal echocardiography, is unchanged during xenon anaesthesia. The lack of effect of xenon on cardiac contractility was confirmed in preparations of isolated guinea pig ventricular muscle bundles; in comparison, in the same study, isoflurane was found to decrease myocardial force development by 30%. Xenon induced no obvious electrical, mechanical, or metabolic cardiac effects, or nitric oxide-dependent flow response in isolated guinea pig hearts. These ‘inert’ cardiac properties of this noble gas probably have their basis in the fact that xenon has little effect on major cation currents including those for sodium [I\textsubscript{Na}], calcium [I\textsubscript{Ca}], or potassium [I\textsubscript{K}], in guinea pig myocytes.

Even in the presence of compromised myocardium, xenon anaesthesia is remarkably stable. In a study of 20 patients undergoing elective coronary artery bypass grafting, xenon decreased indices of cardiac function significantly less than nitrous oxide. Heart rate did not change significantly although it tended to decrease, and the cardiac output and sympathetic tone were maintained in these patients with limited cardiovascular reserve.

In animal models of cardiac disease, the beneficial properties of xenon are further revealed. Rabbits with chronically compromised left ventricular function (through coronary artery ligation), exhibit no cardiac deterioration, and the echocardiographic changes were insignificant with 70% xenon. Furthermore, inhaled xenon (70%) during early reperfusion after coronary artery occlusion reduced infarct size after regional ischaemia in the rabbit heart in vivo. In dogs with pacing-induced cardiomyopathy, the addition of xenon produced minimal cardiovascular effects.

**Neuroprotection**

As stated above, xenon is an inhibitor of glutamatergic NMDA receptors. As activation of the NMDA receptor appears to be crucial to the initiation of neuronal injury...
and death from a variety of insults, xenon’s putative neuroprotective effects have been examined in a series of in vitro and in vivo studies.

In a primary culture of neuronal and glial cells from the cerebral cortex of neonatal mice, predictable injury (reflected by the amount of LDH released into the culture medium) can be produced with either NMDA, glutamate, or oxygen deprivation. In order to assess the possible neuroprotective effects of xenon, LDH assays were performed after brief exposures to either NMDA or glutamate, in the presence of increasing concentrations of xenon. LDH release was significantly reduced at all concentrations tested (Fig. 2) with xenon IC$_{50}$ concentrations for neuroprotection being 19 (6) and 28 (8)% atm for NMDA and glutamate-induced injury, respectively. Xenon was also effective in protecting against the injury caused by depriving the cell cultures of oxygen for 90 mins with an IC$_{50}$ concentration of 10 (4)% atm. As the MAC of xenon has most recently been estimated as 63%, the concentrations required for neuroprotection are significantly sub-anaesthetic. Thus, in contrast to other anaesthetics that require anaesthetic or supra-anaesthetic doses to act as a neuroprotectant, xenon may be effective at more clinically acceptable concentrations.

In an in vivo model of brain injury in rats, xenon, in a concentration-dependent manner, reduced neuronal degeneration provoked by N-methyl DL-aspartate (NMA) administration in the arcuate nucleus of the hypothalamus (Fig. 3). In this model, neuromotor skills, visuospatial memory, and spatial memory were assessed for up to 12 days after rats were subjected to CPB in the presence of either xenon or nitrogen 65% atm. Neurocognitive dysfunction after CPB was attenuated by xenon, which proved to be superior to that seen with another NMDA antagonist, MK801 (dizocilpine) (Figs 4–6).

Previously, several NMDA receptor antagonists have shown remarkable efficacy against neurological injury in pre-clinical models of cerebral injury, but have failed to live up to their promise when subsequently investigated in clinical settings. In some instances, this is because of unfavourable pharmacological properties preventing rapid transfer of the NMDA antagonist across the blood–brain barrier. Almost all NMDA antagonists tested thus far exhibit psychomimetic behavioural changes.
damage in the posterior cingulate and retrosplenial cortices (PC/RS) are morphological correlates of the behavioural changes. Ma and colleagues showed that ketamine and nitrous oxide dose-dependently increased c-Fos expression in PC/RS cortices, a neurotoxic feature not caused by xenon (Fig. 7).

Xenon may therefore be a useful agent when protection against acute neurological injury is required. However, it is
important to consider xenon’s effect on cerebral blood flow (CBF) when its use as a neuroprotectant is being contemplated. The most recent study in animals confirms earlier studies that suggest that in the first 5 min of exposure, xenon increases CBF; thereafter, xenon’s effects on CBF appear to reverse. It is notable that despite changes in CBF, reactivity to carbon dioxide is maintained and, therefore, changes in blood flow can be reversed with hyperventilation. Another animal study showed that 0.3 and 0.7 MAC xenon administration did not cause an increase in intracranial pressure (ICP), (while dilating pial arterioles by 10 and 18%, respectively and venules by 2 and 4%, respectively), and preserved carbon dioxide reactivity of the brain vessels.

Investigation into the effects of xenon (33%) inhalation for 20 min in 13 patients, 3 days after severe head injury, showed clinically significant increases in ICP and cerebral perfusion pressure. Despite these changes, there was no deterioration in arteriovenous oxygen difference values which would be indicative of cerebral oligoemia or ischaemia.

Xenon’s effect on cerebral metabolic rate needs clarification. Frietsch and colleagues found no significant changes in metabolism although cerebral glucose utilization decreased in 18 of 40 brain structures investigated with xenon at 70% atm. Plougmann and colleagues suggested that xenon was not metabolically neutral as they found fluctuations in the arteriovenous oxygen difference. It is also apparent from this study that there is a great deal of individual variation in the effects of xenon in head-injured patients. More research is required in humans to define the impact of xenon anaesthesia on cerebral metabolic and haemodynamic variables.

**Analgesia**

Xenon exhibits more potent analgesic action than nitrous oxide, the only other anaesthetic gas with true analgesic efficacy. Supplementation with fentanyl was lower in a xenon-based anaesthetic compared with that of nitrous oxide (fentanyl 0.05 vs 0.24 mg), and fewer patients required supplementation (35 vs 95%). As changes in haemodynamic variables were used as surrogate markers of the need for further fentanyl, the study may be biased because of the independent effects of each drug on these variables (none with xenon vs sympathetic stimulation with nitrous oxide). Analgesic efficacy was investigated using a different approach in which the fentanyl concentrations required to suppress both somatic (Cp50) and haemodynamic (Cp50-BAR) responses were measured in patients at the time of incision. In the presence of 0.7 MAC nitrous oxide, significantly higher concentrations of fentanyl were required (Cp50 of 3.26 ng ml⁻¹; Cp50-BAR 4.17 ng ml⁻¹) compared with patients receiving 0.7 MAC xenon (Cp50 0.72 ng ml⁻¹ and Cp50-BAR 0.94 ng ml⁻¹). As both sevoflurane and xenon are relatively haemodynamically stable, cardiovascular variables in response to painful stimuli can be used as surrogates to directly compare the analgesic efficacy of these two drugs. Using this approach, xenon is three times more efficacious at blocking cardiovascular responses to incision than sevoflurane at equi-MAC concentrations.

The difference in analgesic potency between nitrous oxide and xenon is more difficult to define when tested in volunteers with ‘experimental pain’. When heat stimulation was used to provoke pain, nitrous oxide and xenon were equivalent analgesics. When electrical stimulation is used to provoke pain, xenon is 1.5 times more potent than nitrous oxide.

In pre-clinical studies designed to determine the mechanism of analgesic action, it appears that xenon differs from nitrous oxide although both these gases are NMDA receptor antagonists. Nitrous oxide provokes release of endogenous ligands for opiate receptors in the periaqueductal grey region, which indirectly activates descending inhibitory neurons in the spinal cord. Here, the released norepinephrine activates adrenergic receptors to mediate the antinociceptive effect. Yet, neither an opiate antagonist nor an α₂ adrenergic antagonist attenuated the antinociceptive properties of xenon. Comparison between the effects of nitrous oxide and xenon on spinal cord dorsal horn neurons in spinal cord transected cats anaesthetized with alpha-chloralose and urethane demonstrated that while xenon suppressed the effects of both pinch and touch on the firing of wide dynamic range neurons, nitrous oxide was...
ineffective. Thus, Adachi and colleagues postulated that the antinociceptive action of xenon was greater at the level of the spinal cord than nitrous oxide, with no role for descending inhibitory systems in its analgesic effect, a finding supported by their earlier work.

**Toxicity**

*In vivo* and *in vitro* experiments suggest that xenon does not trigger malignant hyperthermia (MH) in MH-susceptible swine. Burov and colleagues reported no evidence of toxicity in several *in vitro* and *in vivo* paradigms involving two species given xenon either acutely or sub-chronically. Studies of microorganisms and mice showed xenon has no mutagenic or carcinogenic properties. No embryotoxic or teratogenic changes were found in pregnant Wistar rats, nor xenon found to be allergenic. Xenon was shown to moderately stimulate the immune response and increase the cellularity of lymphoid organs.

**Pharmacoeconomics**

Xenon is an expensive gas; the current cost of 1 litre of xenon with a purity of 99.99% is approximately $10, but may change depending on ‘market forces’. Therefore, closed-circuit delivery appears to be an economic necessity for the application of xenon anaesthesia. An analysis of the cost of a 40-yr-old ASA I, adult male weighing 70 kg undergoing simulated elective surgery, found that 240 min of closed-circuit xenon anaesthesia would cost $356. The bulk of this cost is attributed to the priming and flushing of the delivery circuit; if the delivery technology could be refined to remove nitrogen without the need for priming and flushing, then xenon anaesthesia would cost a more affordable $108, assuming the availability of the closed-circuit delivery device.

Among the recent technological advances to improve the cost-efficiency of xenon anaesthesia are xenon recycling systems, including one pioneered by Burov and colleagues in Russia, in which xenon can be purified to more than 99%. For the efficient use of the recycling system, anaesthesia would have to be maintained with another agent while xenon was recovered.

**Environmental effect**

The ecological impact of an anaesthetist’s work is increasingly coming under scrutiny. Our major volatile anaesthetics are CFC based and are known to deplete the ozone layer. Nitrous oxide is 230 times more potent as a greenhouse gas than carbon dioxide, takes 120 yr to breakdown, and the amount released as an anaesthetic contributes 0.1% of the greenhouse effect. In comparison, xenon appears to be environmentally safe.

**Conclusions**

Xenon is a potent inhalation anaesthetic with many salubrious qualities; expense has so far mitigated the development of its use for anaesthesia, but recent research has suggested a niche for xenon, based on its pharmacokinetic, cardiac, neuroprotective, and analgesic properties.
For example, xenon may be the anaesthetic of choice for ‘fast-track’ cardiac surgery where its rapid emergence, cardio-stability, and neuroprotective qualities can come to the fore. Furthermore, settings in which the risk of intraoperative neurological injury is high (e.g. major intracranial vascular surgery) may be another opportunity for the clinical application of xenon. We await the results of clinical trials to investigate whether neurocognitive deficits can be reduced by the administration of xenon in cardiac surgical patients.

References
1 Allen HL, Iversen LL. Phencyclidine, dizocilpine, and cerebrocortical neurons. Science 1990; 240: 221
6 Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113: 580–2
14 Gajraj RJ, Doi M, Mantzaridis H, Kenny GN. Analysis of the EEG bispectrum, auditory evoked potentials and the EEG power spectrum during repeated transitions from consciousness to unconsciousness. Br J Anaesth 1998; 80: 46–52
15 Glass PS, Doherty M, Jacobs JR, Goodman D, Smith LR. Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. Anesthesiology 1993; 78: 842–7
21 Ishiguro Y. Cardiovascular effects of xenon. Int Anesthesiol Clin 2001; 39: 77–84
43 Morioka N, Ozaki M, Matsukawa T, Sessler D, Atarashi K, Suzuki H. Ketamine causes a paradoxical increase in the Bispectral Index. Anesthesiology 1997; 87: A502
51 Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244: 1360–2
56 Rampil IJ. A primer for EEG signal processing in anesthesia. Anesthesiology 1998; 89: 980–1002
58 Stowe DF, Rehmert GC, Kwok WM, Weigt HU, Georgieff M, Bosnjak ZJ. Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. Anesthesiology 2000; 92: 516–22
64 Wilhelm S, Ma D, Maze M, Franks NP. Effects of xenon on in vivo and in vivo models of neuronal injury. Anesthesiology 2002; 96: 1485–91
67 Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 2000; 93: 1095–101
68 Young C, Moretti E, Hsu Y, Ping J, Somma J. Sedation and arousal associated with dexmedetomidine infusion. Anesthesiology 2001; 95: A276